doi: 10.1016/j.clinre.2016.11.009 Summary Keywords glucagon-like peptide-1 receptor agonists, metabolic disease, metabolic dysfunction-associated steatotic liver disease, public health, umbrella review Citation Wu H, Zhang Z-H, Ye T, Chen J-N, Tung T-H and Zhu J-S (2026) Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review
10 jednostek = 250 mcg
Doses increase weekly during the first two months, then hold steady at a maintenance level
follow-up on weight loss maintenance found 20 to 30 percent of GLP-1 stoppers maintained 50 percent or more of their loss at 1 year
Side Effects, Risks, and Safety Considerations The most common side effects are gastrointestinal nausea, vomiting, and diarrhoea with more serious risks including pancreatitis, gallbladder disease, and elevated resting heart rate
- Clayton Clinical Therapeutics Side Effects and Safety Like most peptides and medications, PT-141 carries some potential side effects